S&P 500   3,116.19 (-0.14%)
DOW   27,975.99 (-0.10%)
QQQ   202.48 (-0.21%)
CGC   15.16 (-1.11%)
BABA   186.98 (+0.80%)
GE   11.48 (-0.35%)
F   9.04 (+1.01%)
PRI   130.62 (+0.00%)
DIS   144.73 (+0.04%)
S&P 500   3,116.19 (-0.14%)
DOW   27,975.99 (-0.10%)
QQQ   202.48 (-0.21%)
CGC   15.16 (-1.11%)
BABA   186.98 (+0.80%)
GE   11.48 (-0.35%)
F   9.04 (+1.01%)
PRI   130.62 (+0.00%)
DIS   144.73 (+0.04%)
S&P 500   3,116.19 (-0.14%)
DOW   27,975.99 (-0.10%)
QQQ   202.48 (-0.21%)
CGC   15.16 (-1.11%)
BABA   186.98 (+0.80%)
GE   11.48 (-0.35%)
F   9.04 (+1.01%)
PRI   130.62 (+0.00%)
DIS   144.73 (+0.04%)
S&P 500   3,116.19 (-0.14%)
DOW   27,975.99 (-0.10%)
QQQ   202.48 (-0.21%)
CGC   15.16 (-1.11%)
BABA   186.98 (+0.80%)
GE   11.48 (-0.35%)
F   9.04 (+1.01%)
PRI   130.62 (+0.00%)
DIS   144.73 (+0.04%)
Log in

Fortress Biotech Stock Price, Forecast & Analysis (NASDAQ:FBIO)

+0.13 (+7.88 %)
(As of 11/18/2019 08:58 AM ET)
Today's Range
Now: $1.78
50-Day Range
MA: $1.37
52-Week Range
Now: $1.78
Volume421,200 shs
Average Volume295,390 shs
Market Capitalization$125.99 million
P/E RatioN/A
Dividend YieldN/A
Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FBIO



Sales & Book Value

Annual Sales$26.88 million
Book Value$1.06 per share


Net Income$-84,150,000.00
Net Margins-143.08%


Market Cap$125.99 million
Next Earnings Date3/16/2020 (Estimated)

Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.

Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How were Fortress Biotech's earnings last quarter?

Fortress Biotech (NASDAQ:FBIO) released its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.22. The biopharmaceutical company had revenue of $9.25 million for the quarter, compared to analyst estimates of $7.51 million. Fortress Biotech had a negative net margin of 143.08% and a negative return on equity of 131.74%. View Fortress Biotech's Earnings History.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Fortress Biotech.

What price target have analysts set for FBIO?

3 brokerages have issued 12-month target prices for Fortress Biotech's shares. Their forecasts range from $4.00 to $19.00. On average, they expect Fortress Biotech's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 536.7% from the stock's current price. View Analyst Price Targets for Fortress Biotech.

What is the consensus analysts' recommendation for Fortress Biotech?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech.

What are Wall Street analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:
  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (7/15/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (5/13/2019)

Has Fortress Biotech been receiving favorable news coverage?

News articles about FBIO stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fortress Biotech earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View News Stories for Fortress Biotech.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a decrease in short interest in October. As of October 31st, there was short interest totalling 1,290,000 shares, a decrease of 7.9% from the September 30th total of 1,400,000 shares. Based on an average trading volume of 327,300 shares, the short-interest ratio is presently 3.9 days. Approximately 2.7% of the shares of the company are short sold. View Fortress Biotech's Current Options Chain.

Who are some of Fortress Biotech's key competitors?

What other stocks do shareholders of Fortress Biotech own?

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the folowing people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 64)
  • Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 62)
  • Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 53)
  • Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 57)
  • Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 65)

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (0.29%), Shikiar Asset Management Inc. (0.26%), Rational Advisors LLC (0.11%) and Tower Research Capital LLC TRC (0.08%). Company insiders that own Fortress Biotech stock include George Avgerinos and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech.

Which major investors are buying Fortress Biotech stock?

FBIO stock was acquired by a variety of institutional investors in the last quarter, including Shikiar Asset Management Inc., Rational Advisors LLC, FNY Investment Advisers LLC and Tower Research Capital LLC TRC . View Insider Buying and Selling for Fortress Biotech.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $1.78.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $125.99 million and generates $26.88 million in revenue each year. The biopharmaceutical company earns $-84,150,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.View Additional Information About Fortress Biotech.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is http://www.fortressbiotech.com/.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]

MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  492
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel